NEW YORK (GenomeWeb News) — MDS this week filed with the Toronto Stock Exchange to buy back up to 4.5 million of its common shares over the next 12 months.
 
The potential buyback relates to MDS’ shares that trade on the Toronto exchange and will not affect the company’s shares that trade on the New York Stock Exchange.
 
As of June 26, MDS had 122.5 million shares issued and outstanding on the Toronto Stock Exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.